Why Are Weight-Loss Stocks Gaining Thursday? - Viking Therapeutics ( NASDAQ:VKTX ) , Novo Nordisk ( NYSE:NVO ) , Structure Therapeutics ( NASDAQ:GPCR ) , Terns Pharma ( NASDAQ:TERN )
Eli Lilly's orforglipron showed 12.4% weight loss vs. 0.9% with placebo, below the 15% expected. Novo Nordisk's CagriSema showed up to 22.7% weight loss over 68 weeks in trials. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
Terns ( TERN ) Q2 Net Loss Narrows 16%
Terns Pharmaceuticals ( NASDAQ:TERN ) , a clinical-stage biopharmaceutical company developing therapies for chronic myeloid leukemia ( CML ) and metabolic diseases, released its second quarter results on August 5, 2025. The most notable news was continued progress in its two lead clinical ...
Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions
Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study. topline data were presented in September ...
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations ...
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635 ( C ) ( 4 )
FOSTER CITY, Calif., May 02, 2025 ( GLOBE NEWSWIRE ) -- Terns Pharmaceuticals, Inc. ( "Terns" or the "Company" ) ( Nasdaq: TERN ) , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, ...
Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals ( TERN ) Looks Ripe for a Turnaround
Terns Pharmaceuticals (TERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the ...
Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals ( TERN )
Terns Pharmaceuticals (TERN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
All You Need to Know About Terns Pharmaceuticals ( TERN ) Rating Upgrade to Buy
Terns Pharmaceuticals (TERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street
Last year, Viking Therapeutics, a mid-cap biotech, made waves after it reported excellent phase 2 results for an investigational medicine for weight loss, the industry's hottest and perhaps fastest-growing therapeutic area.
Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference - Terns Pharma ( NASDAQ:TERN )
TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 New TERN-701 data from ongoing U.S. healthy volunteer PK study shows improved drug-drug interaction profile compared to asciminib
Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference
TERN-701 CARDINAL study progressing well. dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in ...
GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan
€130 million upfront, with eligibility to receive up to €55 million in two additional instalments based on near-term milestones Closing subject to approval by the 2025 OCEANE bondholders at upcoming bondholders meeting Financing would extend cash runway beyond the end of 2027, assuming drawdown ...
GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan
Lille ( France ) , Cambridge ( Massachusetts, United States ) , Zurich ( Switzerland ) , January 30, 2025 - GENFIT ( Nasdaq and Euronext: GNFT ) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases ( the "Company" ) , ...
Top 3 Health Care Stocks You'll Regret Missing In Q4 - Amarin Corp ( NASDAQ:AMRN )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors - Terns Pharma ( NASDAQ:TERN )
FOSTER CITY, Calif., Nov. 18, 2024 ( GLOBE NEWSWIRE ) -- Terns Pharmaceuticals, Inc. ( "Terns" or the "Company" ) TERN, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today ...
Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
Accomplished biotechnology CEO brings 25 years of strategic, operational, and legal experience Accomplished biotechnology CEO brings 25 years of strategic, operational, and legal experience ...
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - ( ALMS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird analyst Brian Skorney initiated coverage on Alumis Inc.
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, PPH, HRTS and THNR
Eli Lilly, Novo Nordisk, PPH, HRTS and THNR are part of the Zacks top Analyst Blog.
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win
In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications.
Tap the Weight-Loss Drug Market With These ETFs
Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
Terns has a modest market cap of less than $800 million, and its possible upside could be massive.
Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday - Applied Therapeutics ( NASDAQ:APLT )
U.S. stocks were mixed, with the Dow Jones index falling around 0.2% on Wednesday. Shares of Applied Therapeutics, Inc. APLT rose sharply during Wednesday's session after the FDA communicated that an advisory committee meeting would no longer be required.
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
Terns Pharmaceuticals just proved that it's competitive in the weight loss field.
Should You Invest in This Under-the-Radar Weight Loss Stock?
Getting in on the ground floor sounds like a great idea, but not if the building ends up crumbling.
1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More
This biotech's data suggests that it could have an advantage in its target market.
Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
FOSTER CITY, Calif., Sept. 12, 2024 ( GLOBE NEWSWIRE ) -- Terns Pharmaceuticals, Inc. ( "Terns" or the "Company" ) ( Nasdaq: TERN ) , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and ...
Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Terns Pharma ( NASDAQ:TERN )
FOSTER CITY, Calif., Sept. 12, 2024 ( GLOBE NEWSWIRE ) -- Terns Pharmaceuticals, Inc. ( "Terns" or the "Company" ) TERN, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today ...
Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More
Terns Pharmaceuticals and Summit Therapeutics are in the spotlight following positive updates on key candidates.
Terns Announces Pricing of Upsized $150.15 Million Public Offering
FOSTER CITY, Calif., Sept. 10, 2024 ( GLOBE NEWSWIRE ) -- Terns Pharmaceuticals, Inc. ( "Terns" or the "Company" ) ( Nasdaq: TERN ) , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and ...
Terns Announces Pricing of Upsized $150.15 Million Public Offering - Terns Pharma ( NASDAQ:TERN )
FOSTER CITY, Calif., Sept. 10, 2024 ( GLOBE NEWSWIRE ) -- Terns Pharmaceuticals, Inc. ( "Terns" or the "Company" ) TERN, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today ...
Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug - Eli Lilly ( NYSE:LLY ) , Amgen ( NASDAQ:AMGN )
Shares of Terns Pharmaceuticals TERN, a clinical-stage company, soared 16.8% after the company announced positive top-line data from the early-stage single and multiple-ascending dose ( SAD and MAD ) obesity study.
Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug
TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant weight reduction compared to placebo.
Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday - Calavo Growers ( NASDAQ:CVGW )
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. Shares of Calavo Growers, Inc. CVGW rose sharply during Tuesday's session as the company posted stronger-than-expected results for its third quarter.
Oracle To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Tuesday - Oracle ( NYSE:ORCL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. TD Cowen raised the price target for Oracle Corporation ORCL from $165 to $180.
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday - Tesla ( NASDAQ:TSLA )
U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Monday. Shares of Terns Pharmaceuticals, Inc. TERN rose sharply in today's pre-market trading session.
Terns Pharmaceuticals' Oral GLP-1 Reaches Phase 1 Finish Line With Encouraging Weight Loss Data After One Month Why Is Terns Pharmaceuticals ( TERN ) Stock Gaining Today? - Terns Pharma ( NASDAQ:TERN )
Monday, Terns Pharmaceuticals Inc. TERN revealed topline data from its Phase 1 single and multiple-ascending dose ( SAD and MAD ) trial to assess the safety, tolerability, pharmacokinetics ( PK ) and pharmacodynamics ( PD ) of TERN-601 dosed once-daily ( QD ) in healthy adults with obesity or ...
Top 2 Health Care Stocks That May Collapse This Quarter - Terns Pharma ( NASDAQ:TERN )
As of Sept. 9, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices ...
Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
Statistically significant mean weight loss up to 5.5% over 28 days ( 4.9% placebo adjusted ...
Terns Surges 29.6% in Three Months: Will the Momentum Continue?
TERN has outperformed the industry in the past three months on encouraging pipeline progress of its candidates. Positive data on obesity candidates should boost the stock further.
Wall Street Analysts Think Terns Pharmaceuticals ( TERN ) Could Surge 78.74%: Read This Before Placing a Bet
The consensus price target hints at a 78.7% upside potential for Terns Pharmaceuticals (TERN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635 ( C ) ( 4 ) - Terns Pharma ( NASDAQ:TERN )
FOSTER CITY, Calif., Aug. 01, 2024 ( GLOBE NEWSWIRE ) -- Terns Pharmaceuticals, Inc. ( "Terns" or the "Company" ) TERN, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today ...
Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition
FOSTER CITY, Calif., July 29, 2024 ( GLOBE NEWSWIRE ) -- Terns Pharmaceuticals, Inc. ( "Terns" or the "Company" ) ( Nasdaq: TERN ) , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, ...
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
At least one of the pair has a credible shot at finding a home in the market.
Ozempic And Wegovy Rivals: Here Are The Companies Working On Competitor Weight Loss Drugs
The stellar success of blockbuster drugs like Ozempic, Wegovy, Mounjaro and Zepbound has companies eager to break into the lucrative weight loss drug market - here are the hopeful rivals preparing to challenge Eli Lilly and Novo Nordisk for dominance in the obesity drug gold rush.
Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday - Methode Electronics ( NYSE:MEI )
U.S. stocks were mostly higher, with the Dow Jones index gaining around 100 points on Thursday. Shares of Methode Electronics, Inc. MEI rose sharply during Thursday's session after the company reported better-than-expected fourth-quarter sales results.
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA's 84th Annual Scientific Sessions and Upcoming Conference Participation
TERN-501 significantly improved the efficacy of a GLP-1 receptor agonist by normalizing energy expenditure, resulting in greater weight loss, increased fat mass loss and relative preservation of lean mass TERN-501 significantly improved the efficacy of a GLP-1 receptor agonist by normalizing ...
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA's 84th Annual Scientific Sessions and Upcoming Conference Participation - Terns Pharma ( NASDAQ:TERN )
FOSTER CITY, Calif., June 21, 2024 ( GLOBE NEWSWIRE ) -- Terns Pharmaceuticals, Inc. ( "Terns" or the "Company" ) TERN, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today ...
Terns ( TERN ) Gains 13.6% YTD: Will the Momentum Continue?
Terns Pharmaceuticals, Inc. (TERN) outperforms the industry year to date on encouraging pipeline progress of its oncology candidate.
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis
Lille ( France ) , Cambridge ( Massachusetts, United States ) , Zurich ( Switzerland ) , June 10, 2024 - GENFIT ( Nasdaq and Euronext: GNFT ) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the ...
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis - Ipsen ( OTC:IPSEY )
Ipsen's Iqirvo® ( elafibranor ) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis ( PBC ) First-ever drug developed in-house by GENFIT to achieve U.S. FDA's approval
